---
title: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice
nct_id: NCT05443191
overall_status: COMPLETED
sponsor: Novo Nordisk A/S
study_type: OBSERVATIONAL
primary_condition: Diabetes Mellitus, Type 2
countries: Finland, France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05443191.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05443191"
ct_last_update_post_date: 2025-12-30
last_seen_at: "2026-05-12T06:04:58.014Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice

**Official Title:** A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Finland

**NCT ID:** [NCT05443191](https://clinicaltrials.gov/study/NCT05443191)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Novo Nordisk A/S
- **Conditions:** Diabetes Mellitus, Type 2
- **Start Date:** 2022-10-20
- **Completion Date:** 2023-04-27
- **CT.gov Last Update:** 2025-12-30

## Brief Summary

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
* Diagnosed with type 2 diabetes mellitus
* The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study
* Male or female, age above or equal to 18 years at the time of signing informed consent
* Available HbA1c value less than or equal to 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit' (V1) if in line with local clinical practice
* Treatment naive to injectable glucose-lowering drug(s). An exception is short-term insulin treatment for acute illness for a total of less than 14 days

Exclusion Criteria:

* Previous participation in this study. Participation is defined as having given informed consent in this study
* Treatment with any investigational drug within 30 days prior to enrolment into the study
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
```

## Arms

- **Semaglutide** — Participants with type 2 diabetes and naive to injectable glucose-lowering treatment.

## Interventions

- **Semaglutide** (DRUG) — Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.

## Primary Outcomes

- **Change in Glycated haemoglobin (HbA1c )** _(time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44))_ — Measured in percentage (%)-points

## Secondary Outcomes

- **Relative change in body weight** _(time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44))_
- **Absolute change in body weight** _(time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44))_
- **HbA1c < 7%** _(time frame: End of Study visit (V3) (week 34-44))_
- **HbA1c reduction >=1%-points and body weight reduction of >=5%** _(time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44))_
- **HbA1c reduction >=1%-points and body weight reduction of >=3%** _(time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44))_
- **DTSQc, relative treatment satisfaction** _(time frame: End of Study visit (V3) (week 34- 44))_
- **DTSQs, change in absolute treatment satisfaction** _(time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44))_

## Locations (3)

- Aava Lääkärikeskus Kamppi, Helsinki, Finland
- Master Centre for Finland, Helsinki, Finland, Finland
- Master centre for France_Paris La défense cedex, Paris, La Défense, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.aava lääkärikeskus kamppi|helsinki||finland` — added _(2026-05-12)_
- `locations.master centre for finland|helsinki, finland||finland` — added _(2026-05-12)_
- `locations.master centre for france_paris la défense cedex|paris|la défense|france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05443191.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05443191*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*